Sanofi has removed chief executive officer Paul Hudson following a stalled turnaround effort and growing pressure around the performance of its vaccine business, marking a significant leadership shift at the French pharmaceutical major. The board decided not to renew Hudson’s mandate after several years at the helm, signalling a push to reset strategy and execution.

The leadership change comes amid investor concerns over slower-than-expected growth, mixed clinical progress, and competitive pressures that weighed on Sanofi’s market performance relative to peers. Analysts have pointed to the need for sharper focus on pipeline delivery, vaccine momentum, and operational discipline.

Sanofi’s board said the transition is intended to position the company for its next growth phase, particularly as it navigates evolving market conditions and prepares for upcoming product cycles. An interim leadership structure will guide operations while the company advances plans for long-term strategic continuity.

The shake-up reflects broader pressures facing large pharmaceutical companies to deliver stronger innovation output and financial performance in a highly competitive global landscape.